Head to head
Regencell Bioscience vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: RGC · TAK
RGC
Regencell Bioscience
4.18-4.13%
1-year price shape — -67% over the period
Quant Rating E · 2/100
vs
TAK
Takeda Pharmaceutical
21.77+1.68%
1-year price shape — +57% over the period
Quant Rating C · 90/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
| RGC | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 4.18 | 21.77 |
| Change today | -4.13% | +1.68% |
| 1-year return | -66.9% | +57.5% |
| Market cap | $2.07B | $69.76B |
| 52-week range | 4.12 – 69.00 | 13.92 – 22.07 |
| Valuation | ||
| P/E (TTM) | -174.17 | 311.00 |
| P/E percentile, own 5-yr range | 41st | 100th |
| P/B | 154.81 | 1.50 |
| Dividend yield | 0.00% | 1.44% |
| Profitability & growth | ||
| EPS (TTM) | -0.02 | -0.30 |
| Net profit (TTM) | $-11.90M | $-970.94M |
| Revenue (TTM) | $3.16B | $4.69T |
| Provider revenue period date | 2017-12-30 | 2026-09-29 |
| Revenue growth (YoY) | +6.0% | +6.7% |
| Gross margin | 62.3% | 65.8% |
| Operating margin | 8.6% | 14.3% |
| Net margin | 3.6% | 0.9% |
| Free cash flow (TTM) | $159.50M | $433.95B |
| Provider cash-flow period date | 2017-12-30 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 0.3% | 51.3% |
| Insider activity (12mo) | 0 buy / 2 sell | 19 buy / 31 sell |
| Short interest (% of float) | 0.1% | 0.1% |
| Analyst consensus | -- | 100% buy (1) |
| Analyst price target | -- | $50 (+132%) |
| StockVane view | ||
| StockVane Quant Rating | E (2) | C (90) |
| Company | ||
| Employees | 10 | 47,029 |
| Founded | 2014 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.